62 results
8-K
EX-99.1
ATHA
Athira Pharma Inc
10 Aug 23
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
4:10pm
; the impact of the COVID-19 pandemic on Athira’s business, research and
clinical development plans and timelines, and the regulatory process … clinical development plans as a result of the COVID-19 pandemic, which could further delay development timelines; the impact of expanded product
8-K
EX-99.1
dykmyhiu61gcf rrm886
22 May 23
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
8:00am
8-K
EX-99.1
ysxmztdcjspwf3e2h1yl
11 May 23
Athira Pharma Reports First Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
o1mr2nzvgo4mn
10 Nov 22
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:11pm
8-K
EX-99.2
dt7ks5gr5jo2111p
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.1
3nkgcbauesmv 0vw2uog
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.1
n4t3gf
15 Aug 22
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:35pm
8-K
EX-99.2
lpae0
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
8-K
EX-99.1
l31oblyy
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
DEFA14A
up9j9u8
17 May 22
Additional proxy soliciting materials
6:06am
DEFA14A
61dcqq
16 May 22
Additional proxy soliciting materials
6:32pm
8-K
EX-99.1
awl3bb04z
12 May 22
Athira Pharma Reports First Quarter 2022 Financial Results
4:12pm